Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Cancer
- Disease
- Antibiotic
- Therapeutic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 276948
License Grant
The Parties have reached an agreement to return rights to certain technologies.
Licensor grants to University a worldwide, exclusive solely for use in the Anthracycline Field License, with right to sublicense for value, the subject matter of U.S. Application No.
09/122,427 (MDA94-031 CON) and its foreign equivalents, including the right to manufacture, use, market and/or sell products or services covered by the Subject Patent, and any divisonals, continuations, resissues, reexaminations or extensions thereof.
Licensor shall discontinue, and shall cause its Subsidiaries and sublicensees to discontinue, the manufacture, use, marketing and sale of Products.
License Property
The term Returned Technology shall mean Licensors rights, including University Patent Rights and rights in University Technical Information, in and to the subject matter and any U.S. or foreign patents, patent applications (including clivisionals, continuations, reissues, reexaminations or extensions thereof) and other intellectual property directed thereto. The patents relate to Anthracyclines.
Anthracyclines are a class of drugs used in cancer chemotherapy that are extracted from Streptomyces bacterium. These compounds are used to treat many cancers, including leukemias, lymphomas, breast, stomach, uterine, ovarian, bladder cancer, and lung cancers.
Field of Use
The term Anthracycline Field as used herein shall include compositions containing, as an active ingredient, Anthracyclines or related DNA-binding agents, such as those exemplified by Annamycin, its derivatives or analogs; methods of delivering said compositions to a patient, tissue or other target; and methods for manufacturing such compositions.
Licensor is a biotechnology company developing technologies and product candidates to treat cancers and infectious diseases, primarily based on immunological approaches.
IPSCIO Record ID: 259856
License Grant
Licensor grants an exclusive sublicense even as to Licensor under the Sublicensed Subject Matter to research, develop, manufacture, have manufactured, use, import, offer to sell and/or sell Sublicensed Products within the Sublicensed Territory for use within the Sublicensed Field.
License Property
The grant is for certain intellectual property rights, including rights to Annamycin, Licensors WP1122 portfolio, and WP1066 portfolio in the field of non-human animals.
Annamycin is an anthracycline antibiotic being investigated for the treatment of cancer.
Field of Use
The Sublicensed Field means the use of Licensed Product for the treatment of cancer in non-human animals through any type of administration.
Licensor is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on discoveries made at M.D. Anderson Cancer Center. The Licensor's clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML.
IPSCIO Record ID: 29382
License Grant
Ixabepilone was developed by the Company, but is subject to a License Agreement with a German Licensor, relating to epothilone technologies.
License Property
Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is an epothilone B analog[1] developed as a cancer drug. Ixempra(ixabepilone) is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs.
The Company manufactures its bulk requirements for ixabepilone in its own facilities including the manufacturing of the active ingredient. The drug product which comprises a pharmaceutical kit is finished by Baxter Oncology GmbH.
Field of Use
In October 2007, the FDA approved ixabepilone in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated, and in monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.
IPSCIO Record ID: 275835
License Grant
University grants to Licensees a non-exclusive license under the Subject Patents for Inventor to practice the inventions covered by such Subject Patents at Licensee.
License Property
The patents are titled
4-Demethoxy-3-desamino-2-halo-anthracycline and pharmaceutical composition containing same,
3-Amino-2 halo-anthracycline antibiotics ,
1-fluoro, 4-fluoro, and 1,4-difluoro-2-halo anthracycline antibiotics, and,
1-fluoro, 4-fluoro, and 1,4-difluoro anthracycline anticancer antibiotics.
Field of Use
The field of use is for research purposes only, including sponsored research, with the right to sublicense both research/development activities and commercial manufacture, use and/or sale.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
